Degree of damage compensation by various pacap treatments in monosodium glutamate-induced retinal degeneration

Norbert Babai, Tamás Atlasz, A. Tamás, D. Reglodi, G. Tóth, P. Kiss, R. Gábriel

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Pituitary adenylate cyclase activating polypeptide (PACAP) has been shown to be neuroprotective in retinal ischemia and monosodium L-glutamate (MSG)-induced retinal degeneration. Here we describe how different MSG treatments (1x and 3x application) cause retinal damage and finally lead to the destruction of the entire inner retina and how PACAP attenuates this effect. Newborn rats from both sexes were injected subcutaneously with 2 mg/g bodyweight MSG on postnatal days 1, 5 and 9. The left eye was left intact while we injected 5 μl PACAP38 solution (100 pmol) into the vitreous of the right eye with a Hamilton syringe at the time of (i) the first, (ii) the first two or (iii) all three MSG injections. Histological analysis has shown that the above described MSG treatment caused the entire inner plexiform layer (IPL) to degenerate, and the inner nuclear (INL) and ganglion cell layers (GCL) seemed fused. One time PACAP38 treatment at the first MSG application did not change the degenerative capacity of MSG. However, if animals received PACAP38 into the vitreous of the eye at the first 2 or all 3 times, a substantial protective effect could be observed. The IPL remained well discernible, the INL retained 2-3 cell rows and the number of cells in the GCL was substantially higher than in the MSG-treated retinas, and was not significantly different from that observed in the control tissue. We conclude that (i) 2 or 3 times PACAP treatment attenuates retinal degeneration; (ii) one PACAP treatment does not provide protection against repeated excitotoxic insults, and (iii) repeated application of PACAP under these experimental conditions may lead to a primed state in which further neurotoxic insults are ineffective.

Original languageEnglish
Pages (from-to)227-233
Number of pages7
JournalNeurotoxicity Research
Volume8
Issue number3-4
DOIs
Publication statusPublished - 2005

Fingerprint

Pituitary Adenylate Cyclase-Activating Polypeptide
Sodium Glutamate
Retinal Degeneration
Glutamic Acid
Therapeutics
Ganglia
Retina
Syringes
Compensation and Redress
Rats
Animals
Ischemia
Cell Count
Cells
Tissue
Injections

Keywords

  • Degeneration
  • Excitotoxicity
  • Glutamate
  • Neuroprotection
  • Neurotoxicity
  • PACAP
  • Retina

ASJC Scopus subject areas

  • Neuroscience(all)
  • Toxicology

Cite this

@article{5a05b77d30cb414aa28ef3a42204bea5,
title = "Degree of damage compensation by various pacap treatments in monosodium glutamate-induced retinal degeneration",
abstract = "Pituitary adenylate cyclase activating polypeptide (PACAP) has been shown to be neuroprotective in retinal ischemia and monosodium L-glutamate (MSG)-induced retinal degeneration. Here we describe how different MSG treatments (1x and 3x application) cause retinal damage and finally lead to the destruction of the entire inner retina and how PACAP attenuates this effect. Newborn rats from both sexes were injected subcutaneously with 2 mg/g bodyweight MSG on postnatal days 1, 5 and 9. The left eye was left intact while we injected 5 μl PACAP38 solution (100 pmol) into the vitreous of the right eye with a Hamilton syringe at the time of (i) the first, (ii) the first two or (iii) all three MSG injections. Histological analysis has shown that the above described MSG treatment caused the entire inner plexiform layer (IPL) to degenerate, and the inner nuclear (INL) and ganglion cell layers (GCL) seemed fused. One time PACAP38 treatment at the first MSG application did not change the degenerative capacity of MSG. However, if animals received PACAP38 into the vitreous of the eye at the first 2 or all 3 times, a substantial protective effect could be observed. The IPL remained well discernible, the INL retained 2-3 cell rows and the number of cells in the GCL was substantially higher than in the MSG-treated retinas, and was not significantly different from that observed in the control tissue. We conclude that (i) 2 or 3 times PACAP treatment attenuates retinal degeneration; (ii) one PACAP treatment does not provide protection against repeated excitotoxic insults, and (iii) repeated application of PACAP under these experimental conditions may lead to a primed state in which further neurotoxic insults are ineffective.",
keywords = "Degeneration, Excitotoxicity, Glutamate, Neuroprotection, Neurotoxicity, PACAP, Retina",
author = "Norbert Babai and Tam{\'a}s Atlasz and A. Tam{\'a}s and D. Reglodi and G. T{\'o}th and P. Kiss and R. G{\'a}briel",
year = "2005",
doi = "10.1007/BF03033976",
language = "English",
volume = "8",
pages = "227--233",
journal = "Neurotoxicity Research",
issn = "1029-8428",
publisher = "Springer New York",
number = "3-4",

}

TY - JOUR

T1 - Degree of damage compensation by various pacap treatments in monosodium glutamate-induced retinal degeneration

AU - Babai, Norbert

AU - Atlasz, Tamás

AU - Tamás, A.

AU - Reglodi, D.

AU - Tóth, G.

AU - Kiss, P.

AU - Gábriel, R.

PY - 2005

Y1 - 2005

N2 - Pituitary adenylate cyclase activating polypeptide (PACAP) has been shown to be neuroprotective in retinal ischemia and monosodium L-glutamate (MSG)-induced retinal degeneration. Here we describe how different MSG treatments (1x and 3x application) cause retinal damage and finally lead to the destruction of the entire inner retina and how PACAP attenuates this effect. Newborn rats from both sexes were injected subcutaneously with 2 mg/g bodyweight MSG on postnatal days 1, 5 and 9. The left eye was left intact while we injected 5 μl PACAP38 solution (100 pmol) into the vitreous of the right eye with a Hamilton syringe at the time of (i) the first, (ii) the first two or (iii) all three MSG injections. Histological analysis has shown that the above described MSG treatment caused the entire inner plexiform layer (IPL) to degenerate, and the inner nuclear (INL) and ganglion cell layers (GCL) seemed fused. One time PACAP38 treatment at the first MSG application did not change the degenerative capacity of MSG. However, if animals received PACAP38 into the vitreous of the eye at the first 2 or all 3 times, a substantial protective effect could be observed. The IPL remained well discernible, the INL retained 2-3 cell rows and the number of cells in the GCL was substantially higher than in the MSG-treated retinas, and was not significantly different from that observed in the control tissue. We conclude that (i) 2 or 3 times PACAP treatment attenuates retinal degeneration; (ii) one PACAP treatment does not provide protection against repeated excitotoxic insults, and (iii) repeated application of PACAP under these experimental conditions may lead to a primed state in which further neurotoxic insults are ineffective.

AB - Pituitary adenylate cyclase activating polypeptide (PACAP) has been shown to be neuroprotective in retinal ischemia and monosodium L-glutamate (MSG)-induced retinal degeneration. Here we describe how different MSG treatments (1x and 3x application) cause retinal damage and finally lead to the destruction of the entire inner retina and how PACAP attenuates this effect. Newborn rats from both sexes were injected subcutaneously with 2 mg/g bodyweight MSG on postnatal days 1, 5 and 9. The left eye was left intact while we injected 5 μl PACAP38 solution (100 pmol) into the vitreous of the right eye with a Hamilton syringe at the time of (i) the first, (ii) the first two or (iii) all three MSG injections. Histological analysis has shown that the above described MSG treatment caused the entire inner plexiform layer (IPL) to degenerate, and the inner nuclear (INL) and ganglion cell layers (GCL) seemed fused. One time PACAP38 treatment at the first MSG application did not change the degenerative capacity of MSG. However, if animals received PACAP38 into the vitreous of the eye at the first 2 or all 3 times, a substantial protective effect could be observed. The IPL remained well discernible, the INL retained 2-3 cell rows and the number of cells in the GCL was substantially higher than in the MSG-treated retinas, and was not significantly different from that observed in the control tissue. We conclude that (i) 2 or 3 times PACAP treatment attenuates retinal degeneration; (ii) one PACAP treatment does not provide protection against repeated excitotoxic insults, and (iii) repeated application of PACAP under these experimental conditions may lead to a primed state in which further neurotoxic insults are ineffective.

KW - Degeneration

KW - Excitotoxicity

KW - Glutamate

KW - Neuroprotection

KW - Neurotoxicity

KW - PACAP

KW - Retina

UR - http://www.scopus.com/inward/record.url?scp=33645953958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645953958&partnerID=8YFLogxK

U2 - 10.1007/BF03033976

DO - 10.1007/BF03033976

M3 - Article

C2 - 16371317

AN - SCOPUS:33645953958

VL - 8

SP - 227

EP - 233

JO - Neurotoxicity Research

JF - Neurotoxicity Research

SN - 1029-8428

IS - 3-4

ER -